Key result
New biomarkers like BNP, CRP, IMA, and MPO offer diagnostic and prognostic value for myocardial ischemia, but their limited specificity necessitates a multi-marker approach.
Why the study?
Do new biochemical markers (BNP, CRP, IMA, MPO) improve the diagnosis and risk stratification of patients with acute coronary syndromes?
Do new biochemical markers (BNP, CRP, IMA, MPO) improve the diagnosis and risk stratification of patients with acute coronary syndromes?
A multi-marker approach incorporating novel biomarkers like BNP, CRP, IMA, and MPO may improve the diagnosis and risk stratification of patients with acute coronary syndromes.
Multi-marker panels may aid ACS evaluation; leaves open prospective validation of specificity and incremental value.
The traditional biomarkers, CK-MB and troponins, used for the diagnosis of myocardial ischemia and the risk stratification of patients with acute coronary syndromes (ACS) are of limited use mainly because they require some degree of necrosis in order to become detectable. Based on the knowledge gained into the pathophysiology of ACS, several new biomarkers have been developed. Brain natriuretic peptides (BNP and NT-proBNP) as markers of hemodynamic stress have shown in several studies a good diagnostic and prognostic performance. C-reactive protein (CRP) reflecting systemic inflammation, has mainly a role as risk stratifier. Ischemia modified albumin (IMA) a pure ischemia marker may offer a substantial aid in diagnosing an acute coronary event in patients with negative troponin. Finally, myeloperoxidase (MPO), a marker of oxidative stress, may also contribute to the diagnosis of ischemia although this is not yet supported by a fair amount of data. Nevertheless, although highly sensitive, these new biomarkers are not specific enough and a multi-marker approach seems the most appropriate strategy for diagnosis of myocardial ischemia and for assessing the risk of an adverse outcome in patients with an acute coronary syndrome.
No takes yet. Share an insight, caveat, or question.
Koulouris et al. (2008) conducted a review in Myocardial ischemia and acute coronary syndromes. New biochemical markers (BNP, CRP, IMA, MPO) vs. Traditional biomarkers (CK-MB, troponins) was evaluated. New biomarkers like BNP, CRP, IMA, and MPO offer diagnostic and prognostic value for myocardial ischemia, but their limited specificity necessitates a multi-marker approach.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: